Jaguar Health (HAM:1JA) Debt-to-Equity : 2.79 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Jaguar Health Debt-to-Equity?

Jaguar Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €9.99 Mil. Jaguar Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €20.79 Mil. Jaguar Health's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €11.04 Mil. Jaguar Health's debt to equity for the quarter that ended in Mar. 2024 was 2.79.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Jaguar Health's Debt-to-Equity or its related term are showing as below:

HAM:1JA' s Debt-to-Equity Range Over the Past 10 Years
Min: -53.02 Med: 1.21 Max: 26.14
Current: 2.79

During the past 11 years, the highest Debt-to-Equity Ratio of Jaguar Health was 26.14. The lowest was -53.02. And the median was 1.21.

HAM:1JA's Debt-to-Equity is ranked worse than
96.34% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HAM:1JA: 2.79

Jaguar Health Debt-to-Equity Historical Data

The historical data trend for Jaguar Health's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health Debt-to-Equity Chart

Jaguar Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.71

0.94

2.53

-53.04

7.48

Jaguar Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															4.67	5.62	26.14	7.48	2.79

Competitive Comparison of Jaguar Health's Debt-to-Equity

For the Biotechnology subindustry, Jaguar Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Debt-to-Equity falls into.

Jaguar Health Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Jaguar Health's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.782	+	29.233)	/	4.549
	=	7.48

Jaguar Health's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.994	+	20.785)	/	11.038
	=	2.79

Jaguar Health (HAM:1JA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Jaguar Health Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health (HAM:1JA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (HAM:1JA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

JAGX:USA 1JAA:Germany

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health (HAM:1JA) Headlines

No Headlines